The lipid-lowering therapy effectiveness and IHD course after coronary stenting
DOI:
https://doi.org/10.26641/2307-0404.2013.2.15947Keywords:
chronic ischemic heart disease, coronary stenting, lipid profile, statinsAbstract
Objective: to examine the relationship between the achievement of goal lipid metabolism and incidence of adverse cardiovascular events in patients after successful coronary stenting. Materials and Methods: The database for the study was data from 198 histories of patients with various forms of ischemic heart disease, who underwent coronary angiography,306 stents implanted in coronary arteries in a regional cardiology center and Mechnikov regional hospital, Dnepropetrovsk over the period from 2004 to 2008. The period of observation of patients was on average 4,6 ± 1,3 years. Results and Discussion: The study found that the best five-year survival rate of patients without adverse cardiovascular events after stenting was significantly associated with previous PCI, presence of stable angina not higher than 2nd FC (61%, p<0,0001), achieving target level of CH-LDL (35%, p = 0.014), TG level less than 1,7 mmol/l was associated with a statistically significant reduction in risk of the primary endpoint 0,68 (long-rank p <0,0001) while taking statins after stenting. Conclusions: Achieving level of total cholesterol less than 4.5 mmol / L was not significantly associated with a decrease in the frequency of adverse CAP after successful stenting, but the level of 5-year survival was significantly associated with the achievement of target levels of LDL cholesterol, less than 2.5 mg/dL and triglycerides less than 1.7 mmol/l.
References
Амосова Е.Н. Эфективность коррекции факто-ров риска и различных методов хирургического лече-ния больных хронической ИБС в отношении пре-дотвра¬щиения смерти и инфаркта миокарда: мифы и реальность / Е.Н. Амосова // Серце і судини. – 2009.– № 4. – С. 12-34.
Коваленко В.М. Регіональні особливості рівня здоров’я народу України / В.М. Коваленко, В.М. Кор-наць¬кий. – К.: Нац. наук. центр «Ін-т кардіології імені акад. М.Д. Стражеска», 2011. – 65 с.
Коваленко В.М. Серцево-судинні захворю-вання. Рекомендації з діагностики, профілактики та лі-ку¬вання / В.М. Коваленко, М.І. Лутай – К.: МОРІОН, 2011. – 408 с.
Леонов В.П. Применение статистики в статьях и диссертациях по медицине и биологии. Ч. II. Исто-рия биометрии и ее применения в России / В.П. Лео¬нов // Междунар. журнал мед. практики. – 2007. – № 4. – С.19.
Лутай М.И. Ведение больных с ишемической болезнью сердца и сопутствующей артериальной ги-пер¬тензией в Украине. Результаты исследования ПРЕСТИЖ / М.И. Лутай // Укр. кардіол. журнал. – 2011. – № 1. – С.25-36.
Методические рекомендации Ассоциации кар-дио¬логов Украины. Дислипидемии: диагностика, про-филактика и лечение. – К., 2007. – 45 с.
Atorvastatin Versus Revascularization Treatments (AVERT) Trial. Presented at. The American Heart As¬sociation. Scientific Sessions. [Электронный ресурс], режим доступа к ресурсу: www.clinicaltrialresults. Org/slides/avert.
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22 / Q.A. Truong, S.A. -Murphy, C.H. McCabe, A. Armani, C.P. Cannon // Circulation. – 2011. – Vol. 4, Issue 3. – P. 328-336.
COURAGE. Clinical Outcomes Utilizing. Revas-cularization and. Aggressive Guideline-Driven. Drug Eva-luation. The First Coronary Angioplasty for Stable CAD[Электронный ресурс], режим доступа к ресурсу www.clinicaltrialresults.org/Slides/COURAGE
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 parti¬cipants in 26 randomised trials/ Cholesterol Treat-ment Trialists' (CTT) Collaboration // Lancet.—2010.—Vol.376, issue 9753.—P. 1670-1681.
ESC/EAS Guidelines for the management of dyslipidaemias/ Zeljko Reiner, Alberico L. Catapano, Guy De Backer [et al.] // Eur. Нeart J. – 2011. – Vol. 32. –P. 1769-1818.
MASS II. Randomized: [ Электронный ресурс], режим доступа к ресурсу: www.clinicaltrialresults. Org/slides/MASS
Relationship of Oxidized Phospholipids and Bio-markers of Oxidized Low-Density Lipoprotein With Car-dio¬vascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes: Results From the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lo-wering) Trial / Alexander E. Fraley MD, Gregory G. Schwartz MD, PhD, Anders G. Olsson MD, PhD [et al.] // JACC. – 2009. – Vol. 52, Issue 23. – P. 2186-2196.
Risk of late stent thrombosis continues for up to 7 years in patients with first generation drug-eluting stents; risk factors identified: (Материалы конгр. транска-тетерной кардиоваск. терапии «TCT2011»), [Элек-трон¬ный ресурс]/Ron Waksman, Martin Leon // EurekAlert.—
Nov.2011.—Режим доступа к журналу: http://www.eurekalert.org/pub_releases/2011-11/crf-rot110911.php.
Non-adherence to dual antiplatelet therapy fol-lowing percutaneous coronary intervention results in hig-her rates of ischemic and bleeding events:(Материалы конгр. транскатетерной кардиоваск. терапии «TCT2011»), [Электронный ресурс] / Roxana Mehran // Me¬dical¬Xpress.—2011.—Режим доступа к журн.: http://medicalxpress.com/news/2011-11-results-paris-registry-tct.html
RITA-2 Trial. PTCA vs. Medical Management of 1018 Stabilized Angina Patients. RITA-2 Trial Parti-cipants: Lancet;350 [Электронный ресурс], режим дос-тупа к ресурсу: www.clinicaltrialresults. Org/slides/tactics-timi
Simple Scoring Scheme For Calculating The Risk Of Acute Coronary Events Based On The 10-Year Fol-low-Up Of The Prospective Cardiovascular Münster (Pro-cam) Study .Электронный ресурс, режим доступа к ресурсу www.clinicaltrialresults.org/Slides/ Procam.
Swiss Interventional Study On Silent Ischemia Type[ Электронный ресурс],режим доступа к ресурсу: www.wikidoc.org/index.php/SWISSI_II
Triglycerides and the risk of coronary heart di-sease. 10158 incident Cases Among 262525 Parti¬cipants in 29 Western Prospective Studies / N. Sarwar, J. Danesh, G. Eiriksdottir [et al.] // Circulation. – 2007. – Vol. 115. – P. 450-458.
Amosova EN. Efektivnost korrektsii faktorov riska i razlichnyih metodov hirurgicheskogo lecheniya bolnyih hronicheskoy IBS v otnoshenii predot¬vra¬schie-niya smerti i infarkta miokarda: mifyi i realnost. Sertse i sudini. 2009;4:12-34.
Kovalenko VM, Kornatskiy VM. Regionalni oso-b¬livosti rivnya zdorov’ya narodu Ukrayini. K: Nats nauk tsentr «In-t kardiologiyi imeni akad MD Strazheska». 2011;65.
Kovalenko VM, Lutay MI. Sertsevo-sudinnI zah-voryuvannya. Rekomendatsiyi z diagnostiki, profilaktiki ta likuvannya. K: MORION. 2011;408.
Leonov VP. Primenenie statistiki v statyah i dis-sertatsiyah po meditsine i biologii. Ch II istoriya biometrii i ee primeneniya v Rossii. Mezhdunar zhurnal med prak-tiki. 2007;4:19.
Lutay MI. Vedenie bolnyih s ishemicheskoy bo-leznyu serdtsa i soputstvuyuschey arterialnoy gipertenziey v Ukraine. Rezultatyi issledovaniya PRESTIZh Ukr kardiol zhurnal. K: Chetverta hvilya. 2011;1:25-36.
Metodicheskie rekomendatsii assotsiatsii kardio-logov Ukrainyi. Dislipidemii: diagnostika, profilaktika i lechenie. K. 2007;45.
Atorvastatin versus revascularization treatments (AVERT) Trial Presented at. The American Heart Asso-ciation. Scientific Sessions: www.clinicaltrialresults. Org/slides/avert.
Truong QA, Murphy SA, McCabe CH, Arma¬ni A, Cannon CP. Benefit of intensive statin therapy in wo-men: results from
PROVE IT-TIMI 22. Circulation. 2011;4(3):328-36.
COURAGE. Clinical Outcomes Utilizing. Revas-cularization and. Aggressive Guideline-Driven. Drug Eva-luation. The First Coronary Angioplasty for Stable CAD. www.clinicaltrialresults.org/Slides/COURAGE.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Cholesterol Treat-ment Trialists' (CTT)
Collaboration. Lancet. 2010;376(9753):1670-81.
Zeljko Reiner, Alberico L Catapano, Guy De Backer. ESC/EAS Guidelines for the management of dyslipidaemias. European heart J. 2011;32:1769-1818.
MASS II. Randomized: www.clinicaltrialresults. Org/slides/MASS.
Alexander E, Fraley MD, Gregory G, Schwartz MD, PhD, Anders G Olsson MD, PhD. Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Fac-tors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes: Results From the MIRACL Myocardial Ischemia Re-duction With Aggressive Cholesterol Lowering. Trial. JACC. 2009;52(23):2186-96.
Ron Waksman, Martin Leon. Risk of late stent thrombosis continues for up to 7 years in patients with first generation drug-eluting stents, risk factors identified: EurekAlert; 9 Nov 2011.
Roxana Mehran. Non-adherence to dual an-tiplatelet therapy following percutaneous coronary inter-vention results in higher rates of ischemic and bleeding events: http://medicalxpress.com/news/2011-11-results-pa¬ris-registry-tct.html. MedicalXpress; 2011.
RITA-2 Trial. PTCA vs. Medical Management of 1018 Stabilized Angina Patients. RITA-2 Trial Parti¬ci-pants: Lancet, 350: www.clinicaltrialresults. Org/slides/tactics-timi.
Simple Scoring Scheme For Calculating The Risk Of Acute Coronary Events Based On The 10-Year Follow-Up Of The Prospective Cardiovascular Münster (Procam) Study: www.clinicaltrialresults.org/Slides/ Procam.
Swiss Interventional Study On Silent Ischemia Type: www.wikidoc.org/index.php/SWISSI_II.
Sarwar N, Danesh J, Eiriksdottir G. Triglycerides and the risk of coronary heart disease. 10158 incident Cases Among 262525 Participants in 29 Western Pro-spective Studies. Circulation. 2007;115:450-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
